Anxiety, Asthma
Conditions
Brief summary
This is a randomized controlled trial to investigate efficacy of a internet-delivered CBT for anxiety related to asthma.
Detailed description
Asthma is one of the most common chronic diseases and is often associated with anxiety. In a two prior studies (ClinicalTrials.gov ID: NCT03158194; NCT03486756) a protocol for exposure-based cognitive behaviour therapy (CBT) for anxiety related to asthma was developed, and standardised to an internet-delivered format and tested for feasibility and acceptability as an internet-CBT. The aim of the current study is to evaluate the efficacy of exposure-based Internet-CBT for anxiety related to asthma compared to Treatment as Usual (TAU). The plan is to include 90 participants consecutively during 2020.
Interventions
BEHAVIORALExposure-based Internet-CBT
Internet-CBT for anxiety-related asthma 8 weekly modules of CBT delivered over the internet and targeting enhanced function and decreased symptoms of anxiety. Participants work independently from home with the treatment and receive support from experienced Internet-CBT Psychologists through written messages in the secure platform. All participants in both conditions can use any other available treatment (TAU), but psychological, from pre-assessments to 2 months after treatment completion.
OTHERTreatment as usual
Patients randomized to treatment as usual will receive the same medical information that participants in the Internet-CBT get, with physiological information about asthma and the importance of medical adherence to achieve well controlled asthma, but without the exposure-based treatment and no therapist support. All participants in both conditions can use any other available treatment (TAU), but psychological, from pre-assessments to 2 months after treatment completion.
Sponsors
Karolinska Institutet
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Masking description
All assessments will be conducted by participants over the internet, why there can be no influence from study staff during data collection.
Intervention model description
The participants will be randomised to immediate internet-CBT or 4 months of treatment as usual before cross-over to internet-CBT.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* asthma diagnosed by a physician * worry about asthma or limitations in daily life due to asthma at
Exclusion criteria
* a serious psychiatric condition; e.g., suicidality, psychosis or severe substance addiction * chronic obstructive pulmonary disease (COPD) or other chronic airway disorders other than asthma
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Catastrophizing about asthma Scale | Time Frame: Baseline to 16 weeks; baseline to 36 weeks; baseline to 12 months. | Change in catastrophizing cognitions about asthma measured with a self-rating scale at baseline, weekly during treatment, at 16 weeks, 36 weeks and 12 months for analysis of effect. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Penn State Worry Questionnaire | Time Frame: Baseline to 8 weeks; baseline to 16 weeks; baseline to 36 weeks; baseline to 12 months. | Change in subjective worry measured with a self-rating scale measured with a self-rating scale at baseline, at 16 weeks, 36 weeks and 12 months for analysis of effect. |
| Asthma Quality of Life Questionnaire | Time Frame: Baseline to 8 weeks; baseline to 16 weeks; baseline to 36 weeks; baseline to 12 months. | Change in asthma-related quality of life measured with a self-rating scale at baseline, at 16 weeks, 36 weeks and 12 months for analysis of effect. |
| Short Health Anxiety Inventory (SHAI) | Time Frame: Baseline to 8 weeks; baseline to 16 weeks; baseline to 36 weeks; baseline to 12 months. | Change in health anxiety measured with a self-rating scale at baseline, at 16 weeks, 36 weeks and 12 months for analysis of effect. |
| Perceived Stress Scale | Time Frame: Baseline to 16 weeks; baseline to 36 weeks; baseline to 12 months. | Change in perceived stress measured with a self-rating scale at baseline, weekly during treatment, at 16 weeks, 36 weeks and 12 months for analysis of effect. |
| Fear of Asthma Symptoms | Time Frame: Baseline to 16 weeks; baseline to 36 weeks; baseline to 12 months. | Change in fear of asthma symptoms measured with a self-rating scale at baseline, weekly during treatment, at 16 weeks, 36 weeks and 12 months for analysis of effect. |
| Asthma Behaviour Checklist | Time Frame: Baseline to 16 weeks; baseline to 36 weeks; baseline to 12 months. | Change in behaviour related to asthma anxiety measured with a self-rating scale at baseline, weekly during treatment, at 16 weeks, 36 weeks and 12 months for analysis of effect. |
| Asthma control test | Time Frame: Baseline to 16 weeks; baseline to 36 weeks; baseline to 12 months. | Change in asthma control measured with a self-rating scale at baseline, weekly during treatment, at 16 weeks, 36 weeks and 12 months for analysis of effect. |
| Patient Health Questionnaire-9 | Time Frame: Baseline to 8 weeks; baseline to16 weeks; baseline to 36 weeks; baseline to 12 months. | Change in depression measured with a self-rating scale at baseline, at 16 weeks, 36 weeks and 12 months for analysis of effect. |
| WHODAS | Time Frame: Baseline to 8 weeks; Baseline to 16 weeks; baseline to 36 weeks; baseline to 12 months. | Change in health related quality of life for health economic evaluation measured with a self-rating scale at baseline, at 16 weeks, 36 weeks and 12 months for analysis of effect. |
| Brunnsviken quality of life scale | Time Frame: Baseline to 8 weeks; baseline to16 weeks; baseline to 36 weeks; baseline to 12 months. | Change in general quality of life measured with a self-rating scale at baseline, at 16 weeks, 36 weeks and 12 months for analysis of effect. |
| Treatment Inventory of Costs in Patients | Time Frame: Baseline to 8 weeks; baseline to16 weeks; baseline to 36 weeks; baseline to 12 months. | Change in health consumption measured with a self-rating scale at baseline, postreatment and at 16 weeks for analysis of effect. |
| Asthma Tuner | Time Frame: Baseline to 8 weeks; baseline to16 weeks. | Change in FEV1 measured with a digital spirometer at baseline, posttreatment and at 16 weeks. |
| Insomnia Severity Index | Time Frame: Baseline to 16 weeks; baseline to 36 weeks; baseline to 12 months. | Change in insomnia measured with a self-rating scale at baseline, at 16 weeks, 36 weeks and 12 months for analysis of effect. |
Countries
Sweden
Outcome results
None listed